Global Therapeutic Vaccines

Therapeutic Vaccines Comprehensive Study by Category (Antigen Vaccines, Dendritic Cell Vaccines, DNA Vaccines, Tumor Cell Vaccines), Disease (Autoimmune Disease, Cancer, Neurological Diseases, Infectious Disease), Technology (Allogeneic Vaccine, Autologous Vaccine), Distribution (Private Vaccine Centers, Hospitals, Governmental Vaccine Centers) Players and Region - Global Market Outlook to 2026

Therapeutic Vaccines Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Therapeutic Vaccines Market Scope
Personalized therapy aims to get the best therapeutic impact on sick tissue with the least amount of off-target adverse effects. Many therapeutic classes have attempted to achieve this goal, but have fallen far short. Therapeutic vaccinations are a new class of treatments that can elicit a dynamic immune response that, in principle, can continue to adapt and increase after immunisation. This flexibility can constantly modify a therapeutic immune response, making it more relevant to the patient's tumour, through epitope spreading or antigen cascade. Long after the vaccination course is finished, this active, dynamic, iterative process might continue. Factors such as prevalence of fatal diseases and infectious viruses have facilitated demand for therapeutic vaccines globally.

The Therapeutic Vaccines market study is segmented and major geographies with country level break-up.

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Therapeutic Vaccines market throughout the predicted period.

Agenus Inc. (United States), Argos Therapeutic Inc. (United States), Merck KGaA (Germany), Celldex Therapeutic Inc. (United States), Cytos Biotechnology AG (Switzerland), Dendreon Corp (United States), GlaxoSmithKline, plc (United Kingdom), Bavarian Nordic (Denmark), CSL Limited (Australia) and Johnson & Johnson (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Medimmune LLC (United States), Novartis AG (Switzerland), Pfizer (United States), Emergent Biosolutions (United States), Vaccinogen Inc. (United States) and Sanofi Pasteur (France).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
AMA Research has segmented the market of Global Therapeutic Vaccines market by Type, Application and Region.

On the basis of geography, the market of Therapeutic Vaccines has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Market Leaders and their expansionary development strategies
On 7th January, 2021 - Merck & Co Completed Its Acquisition of AmpTec to Expand mRNA Capabilities for Vaccines, Treatments and Diagnostics. This Acquisition Adds to Merck's Lipid Manufacturing Expertise, Providing an Integrated Offering Across mRNA Value Chain Globally
On 11th March, 2021 – Moderna Begins Phase 2 of its Booster Covid-19 Vaccine Trials, The Phase 2 Trial Amendment Has Enrolled 60 Participants Who Have Already Received Moderna’s Original mRNA-1273 Vaccine


Market Trend
  • Technical Progress in Medical Industry
  • High Investments in Research & Development

Market Drivers
  • Prevalence of Cancer & Severe Acute Respiratory Syndrome (SARS) Cases
  • Emergence of Advance and Effective Techniques

Opportunities
  • Growth in Healthcare infrastructure Due to Pandemic

Restraints
  • Instability Concerns

Challenges
  • Low Immunogenicity
  • Demand Kinks


Key Target Audience
Therapeutic Vaccines Manufactures, New Entrants and Investors, Therapeutic Vaccines Distributors and Suppliers, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

Report Objectives / Segmentation Covered

By Category
  • Antigen Vaccines
  • Dendritic Cell Vaccines
  • DNA Vaccines
  • Tumor Cell Vaccines

By Disease
  • Autoimmune Disease
  • Cancer
  • Neurological Diseases
  • Infectious Disease

By Technology
  • Allogeneic Vaccine
  • Autologous Vaccine

By Distribution
  • Private Vaccine Centers
  • Hospitals
  • Governmental Vaccine Centers

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Prevalence of Cancer & Severe Acute Respiratory Syndrome (SARS) Cases
      • 3.2.2. Emergence of Advance and Effective Techniques
    • 3.3. Market Challenges
      • 3.3.1. Low Immunogenicity
      • 3.3.2. Demand Kinks
    • 3.4. Market Trends
      • 3.4.1. Technical Progress in Medical Industry
      • 3.4.2. High Investments in Research & Development
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Therapeutic Vaccines, by Category, Disease, Technology, Distribution and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Therapeutic Vaccines (Value)
      • 5.2.1. Global Therapeutic Vaccines by: Category (Value)
        • 5.2.1.1. Antigen Vaccines
        • 5.2.1.2. Dendritic Cell Vaccines
        • 5.2.1.3. DNA Vaccines
        • 5.2.1.4. Tumor Cell Vaccines
      • 5.2.2. Global Therapeutic Vaccines by: Disease (Value)
        • 5.2.2.1. Autoimmune Disease
        • 5.2.2.2. Cancer
        • 5.2.2.3. Neurological Diseases
        • 5.2.2.4. Infectious Disease
      • 5.2.3. Global Therapeutic Vaccines by: Technology (Value)
        • 5.2.3.1. Allogeneic Vaccine
        • 5.2.3.2. Autologous Vaccine
      • 5.2.4. Global Therapeutic Vaccines by: Distribution (Value)
        • 5.2.4.1. Private Vaccine Centers
        • 5.2.4.2. Hospitals
        • 5.2.4.3. Governmental Vaccine Centers
      • 5.2.5. Global Therapeutic Vaccines Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Therapeutic Vaccines: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Agenus Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Argos Therapeutic Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Merck KGaA (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Celldex Therapeutic Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Cytos Biotechnology AG (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Dendreon Corp (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. GlaxoSmithKline, plc (United Kingdom)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Bavarian Nordic (Denmark)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. CSL Limited (Australia)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Johnson & Johnson (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Therapeutic Vaccines Sale, by Category, Disease, Technology, Distribution and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Therapeutic Vaccines (Value)
      • 7.2.1. Global Therapeutic Vaccines by: Category (Value)
        • 7.2.1.1. Antigen Vaccines
        • 7.2.1.2. Dendritic Cell Vaccines
        • 7.2.1.3. DNA Vaccines
        • 7.2.1.4. Tumor Cell Vaccines
      • 7.2.2. Global Therapeutic Vaccines by: Disease (Value)
        • 7.2.2.1. Autoimmune Disease
        • 7.2.2.2. Cancer
        • 7.2.2.3. Neurological Diseases
        • 7.2.2.4. Infectious Disease
      • 7.2.3. Global Therapeutic Vaccines by: Technology (Value)
        • 7.2.3.1. Allogeneic Vaccine
        • 7.2.3.2. Autologous Vaccine
      • 7.2.4. Global Therapeutic Vaccines by: Distribution (Value)
        • 7.2.4.1. Private Vaccine Centers
        • 7.2.4.2. Hospitals
        • 7.2.4.3. Governmental Vaccine Centers
      • 7.2.5. Global Therapeutic Vaccines Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Therapeutic Vaccines: by Category(USD Million)
  • Table 2. Therapeutic Vaccines Antigen Vaccines , by Region USD Million (2015-2020)
  • Table 3. Therapeutic Vaccines Dendritic Cell Vaccines , by Region USD Million (2015-2020)
  • Table 4. Therapeutic Vaccines DNA Vaccines , by Region USD Million (2015-2020)
  • Table 5. Therapeutic Vaccines Tumor Cell Vaccines , by Region USD Million (2015-2020)
  • Table 6. Therapeutic Vaccines: by Disease(USD Million)
  • Table 7. Therapeutic Vaccines Autoimmune Disease , by Region USD Million (2015-2020)
  • Table 8. Therapeutic Vaccines Cancer , by Region USD Million (2015-2020)
  • Table 9. Therapeutic Vaccines Neurological Diseases , by Region USD Million (2015-2020)
  • Table 10. Therapeutic Vaccines Infectious Disease , by Region USD Million (2015-2020)
  • Table 11. Therapeutic Vaccines: by Technology(USD Million)
  • Table 12. Therapeutic Vaccines Allogeneic Vaccine , by Region USD Million (2015-2020)
  • Table 13. Therapeutic Vaccines Autologous Vaccine , by Region USD Million (2015-2020)
  • Table 14. Therapeutic Vaccines: by Distribution(USD Million)
  • Table 15. Therapeutic Vaccines Private Vaccine Centers , by Region USD Million (2015-2020)
  • Table 16. Therapeutic Vaccines Hospitals , by Region USD Million (2015-2020)
  • Table 17. Therapeutic Vaccines Governmental Vaccine Centers , by Region USD Million (2015-2020)
  • Table 18. South America Therapeutic Vaccines, by Country USD Million (2015-2020)
  • Table 19. South America Therapeutic Vaccines, by Category USD Million (2015-2020)
  • Table 20. South America Therapeutic Vaccines, by Disease USD Million (2015-2020)
  • Table 21. South America Therapeutic Vaccines, by Technology USD Million (2015-2020)
  • Table 22. South America Therapeutic Vaccines, by Distribution USD Million (2015-2020)
  • Table 23. Brazil Therapeutic Vaccines, by Category USD Million (2015-2020)
  • Table 24. Brazil Therapeutic Vaccines, by Disease USD Million (2015-2020)
  • Table 25. Brazil Therapeutic Vaccines, by Technology USD Million (2015-2020)
  • Table 26. Brazil Therapeutic Vaccines, by Distribution USD Million (2015-2020)
  • Table 27. Argentina Therapeutic Vaccines, by Category USD Million (2015-2020)
  • Table 28. Argentina Therapeutic Vaccines, by Disease USD Million (2015-2020)
  • Table 29. Argentina Therapeutic Vaccines, by Technology USD Million (2015-2020)
  • Table 30. Argentina Therapeutic Vaccines, by Distribution USD Million (2015-2020)
  • Table 31. Rest of South America Therapeutic Vaccines, by Category USD Million (2015-2020)
  • Table 32. Rest of South America Therapeutic Vaccines, by Disease USD Million (2015-2020)
  • Table 33. Rest of South America Therapeutic Vaccines, by Technology USD Million (2015-2020)
  • Table 34. Rest of South America Therapeutic Vaccines, by Distribution USD Million (2015-2020)
  • Table 35. Asia Pacific Therapeutic Vaccines, by Country USD Million (2015-2020)
  • Table 36. Asia Pacific Therapeutic Vaccines, by Category USD Million (2015-2020)
  • Table 37. Asia Pacific Therapeutic Vaccines, by Disease USD Million (2015-2020)
  • Table 38. Asia Pacific Therapeutic Vaccines, by Technology USD Million (2015-2020)
  • Table 39. Asia Pacific Therapeutic Vaccines, by Distribution USD Million (2015-2020)
  • Table 40. China Therapeutic Vaccines, by Category USD Million (2015-2020)
  • Table 41. China Therapeutic Vaccines, by Disease USD Million (2015-2020)
  • Table 42. China Therapeutic Vaccines, by Technology USD Million (2015-2020)
  • Table 43. China Therapeutic Vaccines, by Distribution USD Million (2015-2020)
  • Table 44. Japan Therapeutic Vaccines, by Category USD Million (2015-2020)
  • Table 45. Japan Therapeutic Vaccines, by Disease USD Million (2015-2020)
  • Table 46. Japan Therapeutic Vaccines, by Technology USD Million (2015-2020)
  • Table 47. Japan Therapeutic Vaccines, by Distribution USD Million (2015-2020)
  • Table 48. India Therapeutic Vaccines, by Category USD Million (2015-2020)
  • Table 49. India Therapeutic Vaccines, by Disease USD Million (2015-2020)
  • Table 50. India Therapeutic Vaccines, by Technology USD Million (2015-2020)
  • Table 51. India Therapeutic Vaccines, by Distribution USD Million (2015-2020)
  • Table 52. South Korea Therapeutic Vaccines, by Category USD Million (2015-2020)
  • Table 53. South Korea Therapeutic Vaccines, by Disease USD Million (2015-2020)
  • Table 54. South Korea Therapeutic Vaccines, by Technology USD Million (2015-2020)
  • Table 55. South Korea Therapeutic Vaccines, by Distribution USD Million (2015-2020)
  • Table 56. Taiwan Therapeutic Vaccines, by Category USD Million (2015-2020)
  • Table 57. Taiwan Therapeutic Vaccines, by Disease USD Million (2015-2020)
  • Table 58. Taiwan Therapeutic Vaccines, by Technology USD Million (2015-2020)
  • Table 59. Taiwan Therapeutic Vaccines, by Distribution USD Million (2015-2020)
  • Table 60. Australia Therapeutic Vaccines, by Category USD Million (2015-2020)
  • Table 61. Australia Therapeutic Vaccines, by Disease USD Million (2015-2020)
  • Table 62. Australia Therapeutic Vaccines, by Technology USD Million (2015-2020)
  • Table 63. Australia Therapeutic Vaccines, by Distribution USD Million (2015-2020)
  • Table 64. Rest of Asia-Pacific Therapeutic Vaccines, by Category USD Million (2015-2020)
  • Table 65. Rest of Asia-Pacific Therapeutic Vaccines, by Disease USD Million (2015-2020)
  • Table 66. Rest of Asia-Pacific Therapeutic Vaccines, by Technology USD Million (2015-2020)
  • Table 67. Rest of Asia-Pacific Therapeutic Vaccines, by Distribution USD Million (2015-2020)
  • Table 68. Europe Therapeutic Vaccines, by Country USD Million (2015-2020)
  • Table 69. Europe Therapeutic Vaccines, by Category USD Million (2015-2020)
  • Table 70. Europe Therapeutic Vaccines, by Disease USD Million (2015-2020)
  • Table 71. Europe Therapeutic Vaccines, by Technology USD Million (2015-2020)
  • Table 72. Europe Therapeutic Vaccines, by Distribution USD Million (2015-2020)
  • Table 73. Germany Therapeutic Vaccines, by Category USD Million (2015-2020)
  • Table 74. Germany Therapeutic Vaccines, by Disease USD Million (2015-2020)
  • Table 75. Germany Therapeutic Vaccines, by Technology USD Million (2015-2020)
  • Table 76. Germany Therapeutic Vaccines, by Distribution USD Million (2015-2020)
  • Table 77. France Therapeutic Vaccines, by Category USD Million (2015-2020)
  • Table 78. France Therapeutic Vaccines, by Disease USD Million (2015-2020)
  • Table 79. France Therapeutic Vaccines, by Technology USD Million (2015-2020)
  • Table 80. France Therapeutic Vaccines, by Distribution USD Million (2015-2020)
  • Table 81. Italy Therapeutic Vaccines, by Category USD Million (2015-2020)
  • Table 82. Italy Therapeutic Vaccines, by Disease USD Million (2015-2020)
  • Table 83. Italy Therapeutic Vaccines, by Technology USD Million (2015-2020)
  • Table 84. Italy Therapeutic Vaccines, by Distribution USD Million (2015-2020)
  • Table 85. United Kingdom Therapeutic Vaccines, by Category USD Million (2015-2020)
  • Table 86. United Kingdom Therapeutic Vaccines, by Disease USD Million (2015-2020)
  • Table 87. United Kingdom Therapeutic Vaccines, by Technology USD Million (2015-2020)
  • Table 88. United Kingdom Therapeutic Vaccines, by Distribution USD Million (2015-2020)
  • Table 89. Netherlands Therapeutic Vaccines, by Category USD Million (2015-2020)
  • Table 90. Netherlands Therapeutic Vaccines, by Disease USD Million (2015-2020)
  • Table 91. Netherlands Therapeutic Vaccines, by Technology USD Million (2015-2020)
  • Table 92. Netherlands Therapeutic Vaccines, by Distribution USD Million (2015-2020)
  • Table 93. Rest of Europe Therapeutic Vaccines, by Category USD Million (2015-2020)
  • Table 94. Rest of Europe Therapeutic Vaccines, by Disease USD Million (2015-2020)
  • Table 95. Rest of Europe Therapeutic Vaccines, by Technology USD Million (2015-2020)
  • Table 96. Rest of Europe Therapeutic Vaccines, by Distribution USD Million (2015-2020)
  • Table 97. MEA Therapeutic Vaccines, by Country USD Million (2015-2020)
  • Table 98. MEA Therapeutic Vaccines, by Category USD Million (2015-2020)
  • Table 99. MEA Therapeutic Vaccines, by Disease USD Million (2015-2020)
  • Table 100. MEA Therapeutic Vaccines, by Technology USD Million (2015-2020)
  • Table 101. MEA Therapeutic Vaccines, by Distribution USD Million (2015-2020)
  • Table 102. Middle East Therapeutic Vaccines, by Category USD Million (2015-2020)
  • Table 103. Middle East Therapeutic Vaccines, by Disease USD Million (2015-2020)
  • Table 104. Middle East Therapeutic Vaccines, by Technology USD Million (2015-2020)
  • Table 105. Middle East Therapeutic Vaccines, by Distribution USD Million (2015-2020)
  • Table 106. Africa Therapeutic Vaccines, by Category USD Million (2015-2020)
  • Table 107. Africa Therapeutic Vaccines, by Disease USD Million (2015-2020)
  • Table 108. Africa Therapeutic Vaccines, by Technology USD Million (2015-2020)
  • Table 109. Africa Therapeutic Vaccines, by Distribution USD Million (2015-2020)
  • Table 110. North America Therapeutic Vaccines, by Country USD Million (2015-2020)
  • Table 111. North America Therapeutic Vaccines, by Category USD Million (2015-2020)
  • Table 112. North America Therapeutic Vaccines, by Disease USD Million (2015-2020)
  • Table 113. North America Therapeutic Vaccines, by Technology USD Million (2015-2020)
  • Table 114. North America Therapeutic Vaccines, by Distribution USD Million (2015-2020)
  • Table 115. United States Therapeutic Vaccines, by Category USD Million (2015-2020)
  • Table 116. United States Therapeutic Vaccines, by Disease USD Million (2015-2020)
  • Table 117. United States Therapeutic Vaccines, by Technology USD Million (2015-2020)
  • Table 118. United States Therapeutic Vaccines, by Distribution USD Million (2015-2020)
  • Table 119. Canada Therapeutic Vaccines, by Category USD Million (2015-2020)
  • Table 120. Canada Therapeutic Vaccines, by Disease USD Million (2015-2020)
  • Table 121. Canada Therapeutic Vaccines, by Technology USD Million (2015-2020)
  • Table 122. Canada Therapeutic Vaccines, by Distribution USD Million (2015-2020)
  • Table 123. Mexico Therapeutic Vaccines, by Category USD Million (2015-2020)
  • Table 124. Mexico Therapeutic Vaccines, by Disease USD Million (2015-2020)
  • Table 125. Mexico Therapeutic Vaccines, by Technology USD Million (2015-2020)
  • Table 126. Mexico Therapeutic Vaccines, by Distribution USD Million (2015-2020)
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Therapeutic Vaccines: by Category(USD Million)
  • Table 138. Therapeutic Vaccines Antigen Vaccines , by Region USD Million (2021-2026)
  • Table 139. Therapeutic Vaccines Dendritic Cell Vaccines , by Region USD Million (2021-2026)
  • Table 140. Therapeutic Vaccines DNA Vaccines , by Region USD Million (2021-2026)
  • Table 141. Therapeutic Vaccines Tumor Cell Vaccines , by Region USD Million (2021-2026)
  • Table 142. Therapeutic Vaccines: by Disease(USD Million)
  • Table 143. Therapeutic Vaccines Autoimmune Disease , by Region USD Million (2021-2026)
  • Table 144. Therapeutic Vaccines Cancer , by Region USD Million (2021-2026)
  • Table 145. Therapeutic Vaccines Neurological Diseases , by Region USD Million (2021-2026)
  • Table 146. Therapeutic Vaccines Infectious Disease , by Region USD Million (2021-2026)
  • Table 147. Therapeutic Vaccines: by Technology(USD Million)
  • Table 148. Therapeutic Vaccines Allogeneic Vaccine , by Region USD Million (2021-2026)
  • Table 149. Therapeutic Vaccines Autologous Vaccine , by Region USD Million (2021-2026)
  • Table 150. Therapeutic Vaccines: by Distribution(USD Million)
  • Table 151. Therapeutic Vaccines Private Vaccine Centers , by Region USD Million (2021-2026)
  • Table 152. Therapeutic Vaccines Hospitals , by Region USD Million (2021-2026)
  • Table 153. Therapeutic Vaccines Governmental Vaccine Centers , by Region USD Million (2021-2026)
  • Table 154. South America Therapeutic Vaccines, by Country USD Million (2021-2026)
  • Table 155. South America Therapeutic Vaccines, by Category USD Million (2021-2026)
  • Table 156. South America Therapeutic Vaccines, by Disease USD Million (2021-2026)
  • Table 157. South America Therapeutic Vaccines, by Technology USD Million (2021-2026)
  • Table 158. South America Therapeutic Vaccines, by Distribution USD Million (2021-2026)
  • Table 159. Brazil Therapeutic Vaccines, by Category USD Million (2021-2026)
  • Table 160. Brazil Therapeutic Vaccines, by Disease USD Million (2021-2026)
  • Table 161. Brazil Therapeutic Vaccines, by Technology USD Million (2021-2026)
  • Table 162. Brazil Therapeutic Vaccines, by Distribution USD Million (2021-2026)
  • Table 163. Argentina Therapeutic Vaccines, by Category USD Million (2021-2026)
  • Table 164. Argentina Therapeutic Vaccines, by Disease USD Million (2021-2026)
  • Table 165. Argentina Therapeutic Vaccines, by Technology USD Million (2021-2026)
  • Table 166. Argentina Therapeutic Vaccines, by Distribution USD Million (2021-2026)
  • Table 167. Rest of South America Therapeutic Vaccines, by Category USD Million (2021-2026)
  • Table 168. Rest of South America Therapeutic Vaccines, by Disease USD Million (2021-2026)
  • Table 169. Rest of South America Therapeutic Vaccines, by Technology USD Million (2021-2026)
  • Table 170. Rest of South America Therapeutic Vaccines, by Distribution USD Million (2021-2026)
  • Table 171. Asia Pacific Therapeutic Vaccines, by Country USD Million (2021-2026)
  • Table 172. Asia Pacific Therapeutic Vaccines, by Category USD Million (2021-2026)
  • Table 173. Asia Pacific Therapeutic Vaccines, by Disease USD Million (2021-2026)
  • Table 174. Asia Pacific Therapeutic Vaccines, by Technology USD Million (2021-2026)
  • Table 175. Asia Pacific Therapeutic Vaccines, by Distribution USD Million (2021-2026)
  • Table 176. China Therapeutic Vaccines, by Category USD Million (2021-2026)
  • Table 177. China Therapeutic Vaccines, by Disease USD Million (2021-2026)
  • Table 178. China Therapeutic Vaccines, by Technology USD Million (2021-2026)
  • Table 179. China Therapeutic Vaccines, by Distribution USD Million (2021-2026)
  • Table 180. Japan Therapeutic Vaccines, by Category USD Million (2021-2026)
  • Table 181. Japan Therapeutic Vaccines, by Disease USD Million (2021-2026)
  • Table 182. Japan Therapeutic Vaccines, by Technology USD Million (2021-2026)
  • Table 183. Japan Therapeutic Vaccines, by Distribution USD Million (2021-2026)
  • Table 184. India Therapeutic Vaccines, by Category USD Million (2021-2026)
  • Table 185. India Therapeutic Vaccines, by Disease USD Million (2021-2026)
  • Table 186. India Therapeutic Vaccines, by Technology USD Million (2021-2026)
  • Table 187. India Therapeutic Vaccines, by Distribution USD Million (2021-2026)
  • Table 188. South Korea Therapeutic Vaccines, by Category USD Million (2021-2026)
  • Table 189. South Korea Therapeutic Vaccines, by Disease USD Million (2021-2026)
  • Table 190. South Korea Therapeutic Vaccines, by Technology USD Million (2021-2026)
  • Table 191. South Korea Therapeutic Vaccines, by Distribution USD Million (2021-2026)
  • Table 192. Taiwan Therapeutic Vaccines, by Category USD Million (2021-2026)
  • Table 193. Taiwan Therapeutic Vaccines, by Disease USD Million (2021-2026)
  • Table 194. Taiwan Therapeutic Vaccines, by Technology USD Million (2021-2026)
  • Table 195. Taiwan Therapeutic Vaccines, by Distribution USD Million (2021-2026)
  • Table 196. Australia Therapeutic Vaccines, by Category USD Million (2021-2026)
  • Table 197. Australia Therapeutic Vaccines, by Disease USD Million (2021-2026)
  • Table 198. Australia Therapeutic Vaccines, by Technology USD Million (2021-2026)
  • Table 199. Australia Therapeutic Vaccines, by Distribution USD Million (2021-2026)
  • Table 200. Rest of Asia-Pacific Therapeutic Vaccines, by Category USD Million (2021-2026)
  • Table 201. Rest of Asia-Pacific Therapeutic Vaccines, by Disease USD Million (2021-2026)
  • Table 202. Rest of Asia-Pacific Therapeutic Vaccines, by Technology USD Million (2021-2026)
  • Table 203. Rest of Asia-Pacific Therapeutic Vaccines, by Distribution USD Million (2021-2026)
  • Table 204. Europe Therapeutic Vaccines, by Country USD Million (2021-2026)
  • Table 205. Europe Therapeutic Vaccines, by Category USD Million (2021-2026)
  • Table 206. Europe Therapeutic Vaccines, by Disease USD Million (2021-2026)
  • Table 207. Europe Therapeutic Vaccines, by Technology USD Million (2021-2026)
  • Table 208. Europe Therapeutic Vaccines, by Distribution USD Million (2021-2026)
  • Table 209. Germany Therapeutic Vaccines, by Category USD Million (2021-2026)
  • Table 210. Germany Therapeutic Vaccines, by Disease USD Million (2021-2026)
  • Table 211. Germany Therapeutic Vaccines, by Technology USD Million (2021-2026)
  • Table 212. Germany Therapeutic Vaccines, by Distribution USD Million (2021-2026)
  • Table 213. France Therapeutic Vaccines, by Category USD Million (2021-2026)
  • Table 214. France Therapeutic Vaccines, by Disease USD Million (2021-2026)
  • Table 215. France Therapeutic Vaccines, by Technology USD Million (2021-2026)
  • Table 216. France Therapeutic Vaccines, by Distribution USD Million (2021-2026)
  • Table 217. Italy Therapeutic Vaccines, by Category USD Million (2021-2026)
  • Table 218. Italy Therapeutic Vaccines, by Disease USD Million (2021-2026)
  • Table 219. Italy Therapeutic Vaccines, by Technology USD Million (2021-2026)
  • Table 220. Italy Therapeutic Vaccines, by Distribution USD Million (2021-2026)
  • Table 221. United Kingdom Therapeutic Vaccines, by Category USD Million (2021-2026)
  • Table 222. United Kingdom Therapeutic Vaccines, by Disease USD Million (2021-2026)
  • Table 223. United Kingdom Therapeutic Vaccines, by Technology USD Million (2021-2026)
  • Table 224. United Kingdom Therapeutic Vaccines, by Distribution USD Million (2021-2026)
  • Table 225. Netherlands Therapeutic Vaccines, by Category USD Million (2021-2026)
  • Table 226. Netherlands Therapeutic Vaccines, by Disease USD Million (2021-2026)
  • Table 227. Netherlands Therapeutic Vaccines, by Technology USD Million (2021-2026)
  • Table 228. Netherlands Therapeutic Vaccines, by Distribution USD Million (2021-2026)
  • Table 229. Rest of Europe Therapeutic Vaccines, by Category USD Million (2021-2026)
  • Table 230. Rest of Europe Therapeutic Vaccines, by Disease USD Million (2021-2026)
  • Table 231. Rest of Europe Therapeutic Vaccines, by Technology USD Million (2021-2026)
  • Table 232. Rest of Europe Therapeutic Vaccines, by Distribution USD Million (2021-2026)
  • Table 233. MEA Therapeutic Vaccines, by Country USD Million (2021-2026)
  • Table 234. MEA Therapeutic Vaccines, by Category USD Million (2021-2026)
  • Table 235. MEA Therapeutic Vaccines, by Disease USD Million (2021-2026)
  • Table 236. MEA Therapeutic Vaccines, by Technology USD Million (2021-2026)
  • Table 237. MEA Therapeutic Vaccines, by Distribution USD Million (2021-2026)
  • Table 238. Middle East Therapeutic Vaccines, by Category USD Million (2021-2026)
  • Table 239. Middle East Therapeutic Vaccines, by Disease USD Million (2021-2026)
  • Table 240. Middle East Therapeutic Vaccines, by Technology USD Million (2021-2026)
  • Table 241. Middle East Therapeutic Vaccines, by Distribution USD Million (2021-2026)
  • Table 242. Africa Therapeutic Vaccines, by Category USD Million (2021-2026)
  • Table 243. Africa Therapeutic Vaccines, by Disease USD Million (2021-2026)
  • Table 244. Africa Therapeutic Vaccines, by Technology USD Million (2021-2026)
  • Table 245. Africa Therapeutic Vaccines, by Distribution USD Million (2021-2026)
  • Table 246. North America Therapeutic Vaccines, by Country USD Million (2021-2026)
  • Table 247. North America Therapeutic Vaccines, by Category USD Million (2021-2026)
  • Table 248. North America Therapeutic Vaccines, by Disease USD Million (2021-2026)
  • Table 249. North America Therapeutic Vaccines, by Technology USD Million (2021-2026)
  • Table 250. North America Therapeutic Vaccines, by Distribution USD Million (2021-2026)
  • Table 251. United States Therapeutic Vaccines, by Category USD Million (2021-2026)
  • Table 252. United States Therapeutic Vaccines, by Disease USD Million (2021-2026)
  • Table 253. United States Therapeutic Vaccines, by Technology USD Million (2021-2026)
  • Table 254. United States Therapeutic Vaccines, by Distribution USD Million (2021-2026)
  • Table 255. Canada Therapeutic Vaccines, by Category USD Million (2021-2026)
  • Table 256. Canada Therapeutic Vaccines, by Disease USD Million (2021-2026)
  • Table 257. Canada Therapeutic Vaccines, by Technology USD Million (2021-2026)
  • Table 258. Canada Therapeutic Vaccines, by Distribution USD Million (2021-2026)
  • Table 259. Mexico Therapeutic Vaccines, by Category USD Million (2021-2026)
  • Table 260. Mexico Therapeutic Vaccines, by Disease USD Million (2021-2026)
  • Table 261. Mexico Therapeutic Vaccines, by Technology USD Million (2021-2026)
  • Table 262. Mexico Therapeutic Vaccines, by Distribution USD Million (2021-2026)
  • Table 263. Research Programs/Design for This Report
  • Table 264. Key Data Information from Secondary Sources
  • Table 265. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Therapeutic Vaccines: by Category USD Million (2015-2020)
  • Figure 5. Global Therapeutic Vaccines: by Disease USD Million (2015-2020)
  • Figure 6. Global Therapeutic Vaccines: by Technology USD Million (2015-2020)
  • Figure 7. Global Therapeutic Vaccines: by Distribution USD Million (2015-2020)
  • Figure 8. South America Therapeutic Vaccines Share (%), by Country
  • Figure 9. Asia Pacific Therapeutic Vaccines Share (%), by Country
  • Figure 10. Europe Therapeutic Vaccines Share (%), by Country
  • Figure 11. MEA Therapeutic Vaccines Share (%), by Country
  • Figure 12. North America Therapeutic Vaccines Share (%), by Country
  • Figure 13. Global Therapeutic Vaccines share by Players 2020 (%)
  • Figure 14. Global Therapeutic Vaccines share by Players (Top 3) 2020(%)
  • Figure 15. Global Therapeutic Vaccines share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Agenus Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 18. Agenus Inc. (United States) Revenue: by Geography 2020
  • Figure 19. Argos Therapeutic Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Argos Therapeutic Inc. (United States) Revenue: by Geography 2020
  • Figure 21. Merck KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 22. Merck KGaA (Germany) Revenue: by Geography 2020
  • Figure 23. Celldex Therapeutic Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. Celldex Therapeutic Inc. (United States) Revenue: by Geography 2020
  • Figure 25. Cytos Biotechnology AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 26. Cytos Biotechnology AG (Switzerland) Revenue: by Geography 2020
  • Figure 27. Dendreon Corp (United States) Revenue, Net Income and Gross profit
  • Figure 28. Dendreon Corp (United States) Revenue: by Geography 2020
  • Figure 29. GlaxoSmithKline, plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 30. GlaxoSmithKline, plc (United Kingdom) Revenue: by Geography 2020
  • Figure 31. Bavarian Nordic (Denmark) Revenue, Net Income and Gross profit
  • Figure 32. Bavarian Nordic (Denmark) Revenue: by Geography 2020
  • Figure 33. CSL Limited (Australia) Revenue, Net Income and Gross profit
  • Figure 34. CSL Limited (Australia) Revenue: by Geography 2020
  • Figure 35. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 36. Johnson & Johnson (United States) Revenue: by Geography 2020
  • Figure 37. Global Therapeutic Vaccines: by Category USD Million (2021-2026)
  • Figure 38. Global Therapeutic Vaccines: by Disease USD Million (2021-2026)
  • Figure 39. Global Therapeutic Vaccines: by Technology USD Million (2021-2026)
  • Figure 40. Global Therapeutic Vaccines: by Distribution USD Million (2021-2026)
  • Figure 41. South America Therapeutic Vaccines Share (%), by Country
  • Figure 42. Asia Pacific Therapeutic Vaccines Share (%), by Country
  • Figure 43. Europe Therapeutic Vaccines Share (%), by Country
  • Figure 44. MEA Therapeutic Vaccines Share (%), by Country
  • Figure 45. North America Therapeutic Vaccines Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Agenus Inc. (United States)
  • Argos Therapeutic Inc. (United States)
  • Merck KGaA (Germany)
  • Celldex Therapeutic Inc. (United States)
  • Cytos Biotechnology AG (Switzerland)
  • Dendreon Corp (United States)
  • GlaxoSmithKline, plc (United Kingdom)
  • Bavarian Nordic (Denmark)
  • CSL Limited (Australia)
  • Johnson & Johnson (United States)
Additional players considered in the study are as follows:
Medimmune LLC (United States) , Novartis AG (Switzerland) , Pfizer (United States) , Emergent Biosolutions (United States) , Vaccinogen Inc. (United States) , Sanofi Pasteur (France)
Select User Access Type

Key Highlights of Report


Jul 2021 217 Pages 71 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Therapeutic Vaccines Quantitative research analysis
Global Therapeutic Vaccines Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a study that suits your business objectives.
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2026.

Know More About Global Therapeutic Vaccines Report?

Have a Query? Click Here

Other Related Reports

Traumatic Brain Injury Therapeutics Comprehensive Study by Type (Immediate emergency care, Medications (Diuretics, Anti-seizure drugs, Coma-inducing drugs, Anti-anxiety agents, Antidepressants, Anti-...
$ 3800
ENT Disorder Treatment Comprehensive Study by Type (Devices, Therapy, Medications (Nasal Spray, Drops, Tablets), Others), Application (Hospitals, Clinics, Ambulatory Surgical Centers, Home Care Setti...
$ 3650
Scar Treatment Comprehensive Study by Type (Surgical, Laser, Topical, Injectable, Other), Application (Hospitals, Dermatology Clinics, Other), Scar (Atrophic, Hypertrophic and Keloid, Contracture, St...
$ 3500
GERD Comprehensive Study by End Users (Hospitals, Diagnostic Centers, Ambulatory Surgical Centers), Route of Administration (Oral, Parenteral, Others), Drug Class (Antacids, Proton Pump Inhibitors, H...
$ 3800
CO2 Incubators Comprehensive Study by Type (Water Jacketed CO2 Incubators, Air-Jacketed CO2 Incubators, Direct Heat CO2 Incubators), Application (Industrial, Biotechnology, Agriculture, Others), Capa...
$ 3450
Gout Drugs Comprehensive Study by Type (Colchicine, Antihyperuricemic Agents (Urate-Lowering Drugs), Non-steroidal Anti-inflammatory Drugs (NSAIDs), Corticosteroids, Others), Application (Clinic, Hos...
$ 3650